Needham & Company
-
Zimmer Biomet (ZBH) PT Lowered to $175 at Needham & Company
-
Zimmer Biomet (ZBH) PT Raised to $202 at Needham & Company Following Earnings
-
Zimmer Biomet (ZBH) PT Raised to $185 at Needham & Company Highlighted as Top Healtcare Pick for 2021
-
Zimmer Biomet (ZBH) PT Raised to $189 at Needham & Company, Following Earnings
-
Zimmer Biomet (ZBH) PT Raised to $187 at Needham & Company, Adds to Conviction List
-
Needham & Company Upgrades Zimmer Biomet (ZBH) to Strong Buy
-
UPDATE: Needham & Company Downgrades Zimmer Biomet (ZBH) to Buy
-
Zimmer Biomet (ZBH) PT Lowered to $146 at Needham & Company
-
Zimmer Biomet (ZBH) PT Raised to $155 at Needham & Company
-
Zimmer Biomet Holdings (ZBH): Buy On Weakness After CEO Departure - Needham
-
Zimmer Biomet (ZBH) PT Raised to $153 at Needham & Company; Buy on Weakness
-
Needham & Company Reiterates Strong Buy Rating and $151 PT on Zimmer Biomet (ZBH) Following Management Meeting
-
Zimmer Biomet (ZBH) PT Raised to $151 at Needham & Company
-
Needham & Company Upgrades Zimmer Biomet (ZBH) to Strong Buy; Supply Issues Only Temporary
-
Streetinsider.com's Hot Lunchtime Reads 7/18: (FCAU) (OMEX) (NVDA) (NFLX)
-
Needham & Company Reiterates Buy as Zimmer Biomet Holdings (ZBH) Acquires Medtech
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Zimmer Biomet (ZBH) PT Raised to $134 at Needham & Company
-
Needham & Company Raised Price Target on Zimmer Biomet Holdings (ZBH) Following Mixed 4Q Results